This product is still under development. Please contact us if you have interest in this product. We will accelerate the development process accordingly and reserve this product for you as request.
Biotinylated Cynomolgus PD-1, His,Avitag (PD1-C82E6) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Gln 167 (Accession # B0LAJ3).
Predicted N-terminus: Leu 25
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag.
The protein has a calculated MW of 19.5 kDa.
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.
- (1) Ishida Y., et al., 1992, EMBO J. 11 (11): 3887–95.
- (2) Blank C., et al., 2007, Cancer Immunol. Immunother. 56 (5): 739–45.
- (3) Agata Y., et al., 1996, Int. Immunol. 8 (5): 765–72.
- (4) Freeman GJ., et al., 2000, J. Exp. Med. 192 (7): 1027–34.
- (5) Latchman Y., et al., 2001, Nat. Immunol. 2 (3): 261–8.
- (6) Yamazaki T., et al., 2002, J. Immunol. 169 (10): 5538–45.